RGC
Price
$12.80
Change
+$0.24 (+1.91%)
Updated
Aug 22 closing price
Capitalization
6.33B
SBFM
Price
$1.40
Change
-$0.02 (-1.41%)
Updated
Aug 22 closing price
Capitalization
6.38M
One day until earnings call
Interact to see
Advertisement

RGC vs SBFM

Header iconRGC vs SBFM Comparison
Open Charts RGC vs SBFMBanner chart's image
Regencell Bioscience Holdings
Price$12.80
Change+$0.24 (+1.91%)
Volume$165.37K
Capitalization6.33B
Sunshine Biopharma
Price$1.40
Change-$0.02 (-1.41%)
Volume$18.89K
Capitalization6.38M
RGC vs SBFM Comparison Chart in %
Loading...
RGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SBFM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGC vs. SBFM commentary
Aug 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGC is a Hold and SBFM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 24, 2025
Stock price -- (RGC: $12.80 vs. SBFM: $1.40)
Brand notoriety: RGC and SBFM are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: RGC: 13% vs. SBFM: 17%
Market capitalization -- RGC: $6.33B vs. SBFM: $6.38M
RGC [@Pharmaceuticals: Generic] is valued at $6.33B. SBFM’s [@Pharmaceuticals: Generic] market capitalization is $6.38M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $69.41B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGC’s FA Score shows that 0 FA rating(s) are green whileSBFM’s FA Score has 0 green FA rating(s).

  • RGC’s FA Score: 0 green, 5 red.
  • SBFM’s FA Score: 0 green, 5 red.
According to our system of comparison, both RGC and SBFM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGC’s TA Score shows that 3 TA indicator(s) are bullish while SBFM’s TA Score has 3 bullish TA indicator(s).

  • RGC’s TA Score: 3 bullish, 3 bearish.
  • SBFM’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, RGC is a better buy in the short-term than SBFM.

Price Growth

RGC (@Pharmaceuticals: Generic) experienced а -2.44% price change this week, while SBFM (@Pharmaceuticals: Generic) price change was -6.03% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +60.15%. For the same industry, the average monthly price growth was +10.62%, and the average quarterly price growth was +74.68%.

Reported Earning Dates

SBFM is expected to report earnings on Aug 25, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+60.15% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGC($6.33B) has a higher market cap than SBFM($6.38M). RGC YTD gains are higher at: 9746.075 vs. SBFM (-53.333). RGC has higher annual earnings (EBITDA): -3.99M vs. SBFM (-6.19M). SBFM has more cash in the bank: 10.3M vs. RGC (2.96M). RGC has less debt than SBFM: RGC (85.7K) vs SBFM (929K). SBFM has higher revenues than RGC: SBFM (36.3M) vs RGC (0).
RGCSBFMRGC / SBFM
Capitalization6.33B6.38M99,232%
EBITDA-3.99M-6.19M64%
Gain YTD9746.075-53.333-18,274%
P/E RatioN/A0.00-
Revenue036.3M-
Total Cash2.96M10.3M29%
Total Debt85.7K929K9%
FUNDAMENTALS RATINGS
RGC vs SBFM: Fundamental Ratings
RGC
SBFM
OUTLOOK RATING
1..100
1863
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3487
P/E GROWTH RATING
1..100
10087
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SBFM's Valuation (40) in the null industry is somewhat better than the same rating for RGC (95) in the Movies Or Entertainment industry. This means that SBFM’s stock grew somewhat faster than RGC’s over the last 12 months.

SBFM's Profit vs Risk Rating (100) in the null industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that SBFM’s stock grew similarly to RGC’s over the last 12 months.

SBFM's SMR Rating (96) in the null industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that SBFM’s stock grew similarly to RGC’s over the last 12 months.

RGC's Price Growth Rating (34) in the Movies Or Entertainment industry is somewhat better than the same rating for SBFM (87) in the null industry. This means that RGC’s stock grew somewhat faster than SBFM’s over the last 12 months.

SBFM's P/E Growth Rating (87) in the null industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that SBFM’s stock grew similarly to RGC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGCSBFM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SBFM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LYRAX29.920.74
+2.54%
Lyrical US Value Equity A
DVLIX32.380.68
+2.15%
BNY Mellon Opportunistic Midcap Value I
MDFGX37.430.75
+2.04%
BlackRock Capital Appreciation Inv A
DIECX46.630.73
+1.59%
BNY Mellon International Core Equity C
VDADX57.390.67
+1.18%
Vanguard Dividend Appreciation Index Adm

RGC and

Correlation & Price change

A.I.dvisor tells us that RGC and QNTM have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGC and QNTM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGC
1D Price
Change %
RGC100%
+1.91%
QNTM - RGC
21%
Poorly correlated
+0.19%
SBFM - RGC
20%
Poorly correlated
-1.41%
ANIP - RGC
11%
Poorly correlated
-0.14%
PCRX - RGC
11%
Poorly correlated
+1.77%
CPIX - RGC
8%
Poorly correlated
+1.54%
More

SBFM and

Correlation & Price change

A.I.dvisor tells us that SBFM and ELAN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
-1.41%
ELAN - SBFM
30%
Poorly correlated
+2.40%
TLRY - SBFM
29%
Poorly correlated
+3.60%
AQST - SBFM
27%
Poorly correlated
+1.79%
CGC - SBFM
26%
Poorly correlated
+2.42%
NBIX - SBFM
25%
Poorly correlated
+0.11%
More